Complete Omis Inc., a leader in clinical proteomics and multi-omics molecular diagnostics, today announced a major milestone with the successful achievement of Clinical Laboratory Improvement Amendments (CLIA) certification and College of American Pathologists (CAP) accreditation.
This accomplishment marks a critical inflection point for the company—transitioning from advanced research innovation to fully regulated clinical deployment, and enabling the delivery of high-complexity, clinical-grade multi-omics testing under the most rigorous standards of quality, reproducibility, and patient care.
From Innovation to Clinical Deployment
CLIA certification and CAP accreditation represent the gold standard for clinical laboratory operations in the United States. These designations validate that Complete Omics’ laboratory infrastructure, assay performance, and quality systems meet stringent regulatory requirements for clinical testing.
With this milestone, Complete Omics has established a clinical-grade operational backbone, enabling its proprietary platforms to move beyond discovery and into real-world clinical application at scale.
Building the Measurement Layer for Precision Medicine
At the core of this transition is Complete Omics’ integrated technology platform, including:
-
Complete360® – an ultra-deep clinical proteomics platform enabling large-scale, high-sensitivity protein quantification
-
Valid-NEO® – a multi-omics platform for neoantigen discovery and validation, supporting next-generation precision oncology
Together, these platforms convert complex biological signals into high-resolution, clinically actionable insights, supporting applications across oncology, cardiovascular disease, neurology, and immunology.
Leadership Perspective
“This milestone represents a defining step in our journey,” said Dr. Qing Wang, Founder and CEO of Complete Omics.
“Achieving CLIA and CAP accreditation validates the rigor of our platform and positions us to bring high-quality, reproducible multi-omics testing directly into clinical settings. We are building the foundational measurement layer for precision medicine—where deep molecular insights can be translated into real impact for patient care.”
Positioned for Clinical Scale and Strategic Expansion
With CLIA and CAP accreditation in place, Complete Omics is now positioned to:
-
Deploy clinical-grade multi-omics assays in real-world settings
-
Expand laboratory-developed test (LDT) offerings
-
Partner with healthcare systems, biopharma, and clinical research organizations
-
Scale high-throughput, regulatory-compliant omics infrastructure
This milestone establishes Complete Omics as a category-defining platform at the intersection of multi-omics, clinical diagnostics, and AI-driven interpretation, with the ability to bridge discovery and clinical impact at scale.
About Complete Omics Inc.
Complete Omics Inc. is a biotechnology company pioneering clinical proteomics and multi-omics diagnostics. The company is focused on building scalable, regulatory-compliant platforms that enable early disease detection, therapeutic guidance, and precision medicine at population scale.
